Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 2/20 | 0.41 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119057 | 0.90 | USP1 (0.40) | USP1WDR48CTSLPDE5ATRPV1 | |
| SCHEMBL5123682 | 0.89 | HRH4 (0.41) | USP1WDR48PDE5A | |
| SCHEMBL5124395 | 0.89 | BCDIN3D (0.45) | PDE5A | |
| SCHEMBL5129478 | 0.89 | PDE5A (0.45) | PDE5A | |
| SCHEMBL5128132 | 0.88 | ICAM1 (0.42) | USP1WDR48CTSLGAA | |
| SCHEMBL5130021 | 0.88 | USP1 (0.46) | USP1WDR48CTSLTRPV1 | |
| SCHEMBL5121505 | 0.87 | CHRM4 (0.39) | USP1WDR48PDE5ADYRK1ACLK4 | |
| SCHEMBL5123475 | 0.86 | USP1 (0.37) | USP1WDR48CTSLPDE5AAURKA | |
| SCHEMBL5114314 | 0.85 | MEN1 (0.46) | PDE5A | |
| SCHEMBL5117435 | 0.85 | MAPT (0.44) | USP1WDR48PDE5ACLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| CN-1875023-A | Use of thienopyrimidines | MERCK PATENT GMBH (DE) | 2006-12-06 | — | — | CN | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| US-6133271-A | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | USP1 2251/4885WDR48 1634/4885CTSL 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.